#gsk — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #gsk, aggregated by home.social.
-
GSK stock holds steady as Q2 2026 earnings and dividend support outlook
GSK plc (GB0009252882) stock is trading close to its recent London closing level as of August 22, 2026,…
#EuropeSays #Britain #Europe #EU #GSK #GB0009252882
https://www.europesays.com/britain/109082/ -
https://www.europesays.com/britain/109082/ GSK stock holds steady as Q2 2026 earnings and dividend support outlook #GB0009252882 #GSK
-
What’s Fresh in the GSK (LSE:GSK) Story This Week?
Highlights GSK is being framed against the current FTSE 100 tape as the UK pharma major balancing pipeline…
#EuropeSays #Britain #Europe #EU #GSK #What
https://www.europesays.com/britain/109044/ -
https://www.europesays.com/britain/109044/ What’s Fresh in the GSK (LSE:GSK) Story This Week? #GSK #What
-
Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
An estimated 450,000 people in Ireland currently have asthma, with approximately 900,000 individuals expected to develop the condition…
#Europe #EU #EuropeanCommission #asthma #bioilogic #depemokimab #Exdensur #GSK
https://www.europesays.com/europe/120832/ -
GSK’s Blenrep combinations approved in Singapore for relapsed or refractory multiple myeloma
GSK’s Blenrep combinations approved in Singapore for relapsed or refractory multiple myeloma August 21, 2026 | Friday |…
#EuropeSays #Britain #Europe #EU #GSK #antibodydrugconjugate #BCMA #belantamabmafodotin #biopharma #Blenrep #DREAMM-7 #DREAMM-8 #HSASingapore #multiplemyeloma #Oncology #relapsedmultiplemyeloma
https://www.europesays.com/britain/108040/ -
https://www.europesays.com/britain/108040/ GSK’s Blenrep combinations approved in Singapore for relapsed or refractory multiple myeloma #AntibodyDrugConjugate #BCMA #BelantamabMafodotin #biopharma #Blenrep #DREAMM7 #DREAMM8 #GSK #HSASingapore #MultipleMyeloma #Oncology #RelapsedMultipleMyeloma
-
GSK CEO targets $2.5B in cost savings from mature products, procurement, supply chain
About half a year into his tenure as GSK’s CEO, Luke Miels is launching a three-year restructuring to…
#EuropeSays #Britain #Europe #EU #GSK #ArtificialIntelligence #Earnings #FiercePharmaHomepage #Financials #LukeMiels #Pharma #restructure #Restructuring
https://www.europesays.com/britain/107958/ -
https://www.europesays.com/britain/107958/ GSK CEO targets $2.5B in cost savings from mature products, procurement, supply chain #ArtificialIntelligence #Earnings #FiercePharmaHomepage #Financials #GSK #LukeMiels #Pharma #restructure #Restructuring
-
New launches, innovative portfolio set to drive gains for GSK Pharma stock | Markets News
In addition to a strong Q1 show, brokerages expect the company to post strong growth in…
#EuropeSays #Britain #Europe #EU #GSK #Arexvy #Blenrep #GlaxoSmithKlinePharmaceuticals #GSKPharma #GSKPharmastock #Jemperli #Nucala #Q1FY27results #Shingrix #Trelegy #Zejula
https://www.europesays.com/britain/107569/ -
https://www.europesays.com/britain/107569/ New launches, innovative portfolio set to drive gains for GSK Pharma stock | Markets News #Arexvy #Blenrep #GlaxoSmithKlinePharmaceuticals #GSK #GSKPharma #GSKPharmaStock #Jemperli #Nucala #Q1FY27Results #Shingrix #Trelegy #Zejula
-
Is GSK drawing fresh attention as vaccine demand shapes the sector this week?
Highlights GSK held sector attention as London healthcare traded on a mixed footing. Vaccines and specialty medicines give…
#EuropeSays #Britain #Europe #EU #GSK #IsGSKdrawingfreshattentionasvaccinedemandshapesthe
https://www.europesays.com/britain/107527/ -
https://www.europesays.com/britain/107527/ Is GSK drawing fresh attention as vaccine demand shapes the sector this week? #GSK #IsGSKDrawingFreshAttentionAsVaccineDemandShapesThe
-
Why Healthcare Stocks Are Back In Focus As London Weighs The Energy Shock
Highlights Healthcare Stocks are active before the London open because drug-pipeline disclosures, half-year reporting and transaction activity are…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/107503/ -
https://www.europesays.com/britain/107503/ Why Healthcare Stocks Are Back In Focus As London Weighs The Energy Shock #GSK
-
Company mergers can cut costs without cutting prices for consumers, study finds | Media Centre
Merging companies might become cheaper and more efficient to run, but savings are not necessarily passed onto shoppers…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/107469/ -
https://www.europesays.com/britain/107469/ Company mergers can cut costs without cutting prices for consumers, study finds | Media Centre #GSK
-
GSK (LSE:GSK) Puts Healthcare Stocks Under An Earnings-Quality Spotlight
Highlights Healthcare Stocks are active before the London open because drug-pipeline disclosures, half-year reporting and transaction activity are…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/107447/ -
https://www.europesays.com/britain/107447/ GSK (LSE:GSK) Puts Healthcare Stocks Under An Earnings-Quality Spotlight #GSK
-
GSK stock advances as management boosts ADS holdings and valuation looks stretched
GSK plc (ISIN GB0009252882) stock is trading firmly after recent management share acquisitions in the company’s American Depositary…
#EuropeSays #Britain #Europe #EU #GSK #GB0009252882
https://www.europesays.com/britain/107236/ -
https://www.europesays.com/britain/107236/ GSK stock advances as management boosts ADS holdings and valuation looks stretched #GB0009252882 #GSK
-
Japan’s Chugai Pharma signs exclusive license agreement with GSK for anti-dengue virus antibody AID351
Japan’s Chugai Pharma signs exclusive license agreement with GSK for anti-dengue virus antibody AID351 August 20, 2026 |…
#EuropeSays #Britain #Europe #EU #GSK #AID351 #Antibody #Chugai #Dengue #Japan
https://www.europesays.com/britain/107162/ -
GSK stock holds steady as analysts maintain a cautious upside outlook
GSK plc (ISIN GB0009252882) stock is trading modestly higher in the latest session, with London-listed shares quoted around…
#EuropeSays #Britain #Europe #EU #GSK #GB0009252882
https://www.europesays.com/britain/107178/ -
https://www.europesays.com/britain/107178/ GSK stock holds steady as analysts maintain a cautious upside outlook #GB0009252882 #GSK
-
Japan’s Chugai Pharma signs exclusive license agreement with GSK for anti-dengue virus antibody AID351
Japan’s Chugai Pharma signs exclusive license agreement with GSK for anti-dengue virus antibody AID351 August 20, 2026 |…
#EuropeSays #Japan #JP #AID351 #antibody #Chugai #Dengue #GSK #Nihon
https://www.europesays.com/japan/77171/ -
Samsung Biologics pays GSK $280M to secure first US manufacturing site
Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making…
#EuropeSays #Korea #KR #SamsungBiologics #Acquisition #Benlysta #drugmanufacturing #Facilities #FiercePharmaHomepage #GSK #HumanGenomeSciences #Manufacturing #manufacturingfacilities #Manufacturingjobs #Maryland #pharma #plantexpansion #Samsung #Tariffs
https://www.europesays.com/korea/125838/ -
Nucala (mepolizumab) receives a positive reimbursement recommendation from CDA-AMC for adults with chronic obstructive pulmonary disease (COPD)
Canada’s Drug Agency (CDA-AMC) affirms the value of Nucala for adults with COPD characterized by raised blood eosinophils. This recommendation…
#EuropeSays #Britain #Europe #EU #GSK #GlaxoSmithKlineInc.
https://www.europesays.com/britain/106751/ -
https://www.europesays.com/britain/106751/ Nucala (mepolizumab) receives a positive reimbursement recommendation from CDA-AMC for adults with chronic obstructive pulmonary disease (COPD) #GlaxoSmithKlineInc #GSK
-
GSK secures preclinical dengue antibody from Chugai
GSK has secured an exclusive, worldwide license from Japan-based Chugai Pharmaceutical Co., Ltd. (Tokyo: 4519) for AID351, a…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/106728/ -
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley
By Nils PratleyPharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders
#Pharmaceuticalsindustry #GSK #UKnews #Business #Cambridge #Cambridgeshire #TheGuardian #NilsPratley
-
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley
By Nils PratleyPharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders
#Pharmaceuticalsindustry #GSK #UKnews #Business #Cambridge #Cambridgeshire #TheGuardian #NilsPratley
-
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley https://www.theguardian.com/business/nils-pratley-on-finance/2026/jul/28/gsk-cambridge-long-awaited-good-vibes #PharmaceuticalsIndustry #UkNews #Business #Gsk
-
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley https://www.theguardian.com/business/nils-pratley-on-finance/2026/jul/28/gsk-cambridge-long-awaited-good-vibes #PharmaceuticalsIndustry #UkNews #Business #Gsk
-
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley https://www.theguardian.com/business/nils-pratley-on-finance/2026/jul/28/gsk-cambridge-long-awaited-good-vibes #PharmaceuticalsIndustry #UkNews #Business #Gsk
-
Padilha anuncia compra do cabotegravir, PrEP de longa duração
No AIDS 2026, ministro da Saúde tornou pública a aquisição do medicamento de HIV. Também informou sobre o impasse do lenacapavir e um acordo para acompanhar o desenvolvimento do alimatravirhttps://outraspalavras.net/outrasaude/padilha-anuncia-compra-do-cabotegravir-prep-de-longa-duracao/
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development
By Joanna PartridgePharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site
#Pharmaceuticalsindustry #GSK #Business #Biotechnologyindustry #UKnews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage #TheGuardian #JoannaPartridge
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development
By Joanna PartridgePharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site
#Pharmaceuticalsindustry #GSK #Business #Biotechnologyindustry #UKnews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage #TheGuardian #JoannaPartridge
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development https://www.theguardian.com/business/2026/jul/28/gsk-cut-jobs-cost-cutting-faster-drug-development-cambridge #PharmaceuticalsIndustry #Gsk #Business #BiotechnologyIndustry #UkNews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development https://www.theguardian.com/business/2026/jul/28/gsk-cut-jobs-cost-cutting-faster-drug-development-cambridge #PharmaceuticalsIndustry #Gsk #Business #BiotechnologyIndustry #UkNews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development https://www.theguardian.com/business/2026/jul/28/gsk-cut-jobs-cost-cutting-faster-drug-development-cambridge #PharmaceuticalsIndustry #Gsk #Business #BiotechnologyIndustry #UkNews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development https://www.theguardian.com/business/2026/jul/28/gsk-cut-jobs-cost-cutting-faster-drug-development-cambridge #PharmaceuticalsIndustry #Gsk #Business #BiotechnologyIndustry #UkNews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage
-
GSK купує американську біотех-компанію Nuvalent за $10,6 млрд — це найбільша угода виробника за останні вісім років. Премумія в 40% свідчить про стратегічний розворот назад до онкології після років скорочення цього напряму.
Злиття та поглинання у фармацевтиці — один із ключових індикаторів настроїв у секторі охорони здоров'я. Коли великі гравці платять значну премію за доступ до нових технологій, це часто дає імпульс суміжним компаніям і підвищує увагу до біотех-стартапів на ранніх стадіях.
Для українського інвестора це нагадування: стежте за M&A активністю у фармі та біотеху — вона часто випереджає загальне зростання сектора.
#GSK #MergersAndAcquisitions #Biotech #Онкологія #Інвестиції #Фармацевтика
-
GSK купує американську біотех-компанію Nuvalent за $10,6 млрд — це найбільша угода виробника за останні вісім років. Премумія в 40% свідчить про стратегічний розворот назад до онкології після років скорочення цього напряму.
Злиття та поглинання у фармацевтиці — один із ключових індикаторів настроїв у секторі охорони здоров'я. Коли великі гравці платять значну премію за доступ до нових технологій, це часто дає імпульс суміжним компаніям і підвищує увагу до біотех-стартапів на ранніх стадіях.
Для українського інвестора це нагадування: стежте за M&A активністю у фармі та біотеху — вона часто випереджає загальне зростання сектора.
#GSK #MergersAndAcquisitions #Biotech #Онкологія #Інвестиції #Фармацевтика
-
GSK to buy US cancer treatment firm Nuvalent for $10.6bn https://www.theguardian.com/business/2026/jun/09/gsk-buy-us-cancer-treatment-firm-nuvalent-luke-miels #Gsk #PharmaceuticalsIndustry #Business #UkNews #UsNews #Cancer #Society
-
GSK to buy US cancer treatment firm Nuvalent for $10.6bn https://www.theguardian.com/business/2026/jun/09/gsk-buy-us-cancer-treatment-firm-nuvalent-luke-miels #Gsk #PharmaceuticalsIndustry #Business #UkNews #UsNews #Cancer #Society
-
GSK to buy US cancer treatment firm Nuvalent for $10.6bn https://www.theguardian.com/business/2026/jun/09/gsk-buy-us-cancer-treatment-firm-nuvalent-luke-miels #Gsk #PharmaceuticalsIndustry #Business #UkNews #UsNews #Cancer #Society
-
Julie Bowen, Ty Burrell Find Advertisers Crave a ‘Modern Family’ Approach to Commercials
#Variety #News #GSK #JulieBowen #ModernFamily #TyBurrellhttps://variety.com/2026/tv/news/julie-bowen-ty-burrell-modern-family-commercials-1236752714/
-
Julie Bowen, Ty Burrell Find Advertisers Crave a ‘Modern Family’ Approach to Commercials
#Variety #News #GSK #JulieBowen #ModernFamily #TyBurrellhttps://variety.com/2026/tv/news/julie-bowen-ty-burrell-modern-family-commercials-1236752714/
-
Julie Bowen, Ty Burrell Find Advertisers Crave a ‘Modern Family’ Approach to Commercials
#Variety #News #GSK #JulieBowen #ModernFamily #TyBurrellhttps://variety.com/2026/tv/news/julie-bowen-ty-burrell-modern-family-commercials-1236752714/
-
Julie Bowen, Ty Burrell Find Advertisers Crave a ‘Modern Family’ Approach to Commercials
#Variety #News #GSK #JulieBowen #ModernFamily #TyBurrellhttps://variety.com/2026/tv/news/julie-bowen-ty-burrell-modern-family-commercials-1236752714/
-
Julie Bowen, Ty Burrell Find Advertisers Crave a ‘Modern Family’ Approach to Commercials
-
O fim de uma patente pode mudar a luta contra o HIV no Brasil
-
Unser MEZIS-Medientipp für heute: "Negativpreis für Gürtelrose-Kampagne von Pharma-Hersteller", Frankfurter Rundschau, 20.04.26.
Und ja, der Preis ist von uns und heißt "Goldenes Zäpfchen" ;-)
-
Unser MEZIS-Medientipp für heute: "Negativpreis für Gürtelrose-Kampagne von Pharma-Hersteller", Frankfurter Rundschau, 20.04.26.
Und ja, der Preis ist von uns und heißt "Goldenes Zäpfchen" ;-)
-
Unser MEZIS-Medientipp für heute: "Negativpreis für Gürtelrose-Kampagne von Pharma-Hersteller", Frankfurter Rundschau, 20.04.26.
Und ja, der Preis ist von uns und heißt "Goldenes Zäpfchen" ;-)
-
GSK reports promising early results in ovarian and womb cancer drug trial https://www.theguardian.com/business/2026/apr/12/gsk-promising-early-results-ovarian-womb-cancer-drug-trial #Gsk #PharmaceuticalsIndustry #Business #UkNews #Cancer #MedicalResearch #Health #Drugs #ManufacturingSector #WomensHealth
